Dragica Radojković, PhD

Dragica Radojković, PhD is a molecular biologist with the expertise in human molecular genetics. She is in charge of genetic testing for cystic fibrosis, CFTR related disorders, thrombophilia and A1AT deficiency in the Institute of Molecular genetics and Genetic Engineering, Belgrade and lecturer at Faculty of Biology, Belgrade University, Serbia. Her research interest is in the field of molecular basis of CFTR related disorders and coagulation diseases. She actively participated or coordinated several national and international research projects. She is currently a principal investigator of the project Genomic elements in phenotype modulation (funded by MSEPRS, 143051, 2006-2010) and partner in a EU project "EUROGENTEST, Network of excellence, FP6-512148 (2005-2009). She is a national coordinator of ORPHANET database, coordinator of Serbian National Mutation database and collaborator of CFTR2 database.

Recent publications

1. Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.Heylen E, Miljic P, Willemse J, Djordjevic V, **Radojkovic D**, Colovic M, Elezovic I, Hendriks D.Thromb Res. 2009 Feb 3. Epub ahead of print
2. Matrix Metalloproteinases Gene Variants in Idiopathic Disseminated Bronchiectasis. Stankovic M, Nikolic A, Divac A, Rakicevic L, Tomovic A, Mitic-Milikic M, Nagorni-Obradovic L, Grujic M, Petrovic-Stanojevic N, Andjelic-Jelic M, Dopudja-Pantic V, **Radojkovic D.** J Investig Med. 2009 Jan 31. [Epub ahead of print]
3. A1ATVar: a relational database of human SERPINA1 gene variants leading to alpha1-antitrypsin deficiency and application of the VariVis software. Zaimidou S, van Baal S, Smith TD, Mitropoulos K, Ljujic M, **Radojkovic D**, Cotton RG, Patrinos GP. Hum Mutat. 2009 Mar; 30(3):308-13.
4. The CFTR M470V gene variant as a potential modifier of COPD severity: study of Serbian population. Stankovic M, Nikolic A, Divac A, Tomovic A, Petrovic-Stanojevic N, Andjelic M, Dopudja-Pantic V, Surlan M, Vujicic I, Ponomarev D, Mitic-Milikic M, Kusic J, **Radojkovic D.**Genet Test. 2008 Sep; 12(3):357-62.
5. MTHFR C677T polymorphism in chronic pancreatitis and pancreatic adenocarcinoma. Nisevic I, Dinic J, Nikolic A, Djordjevic V, Lukic S, Ugljesic M, Andjelic-Jelic M, Petrovic-Stanojevic N, **Radojkovic D.** Cell Biochem Funct. 2008 Aug; 26(6):659-63.
6. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. Castellani C, Cuppens H, Macek M Jr, Cassiman JJ, Kerem E, Durie P, Tullis E, Assael BM, Bombieri C, Brown A, Casals T, Claustres M, Cutting GR, Dequeker E, Dodge J, Doull I, Farrell P, Ferec C, Girodon E, Johannesson M, Kerem B, Knowles M, Munck A, Pignatti PF, **Radojkovic D**, Rizzotti P, Schwarz M, Stuhrmann M, Tzetis M, Zielenski J, Elborn JS. J Cyst Fibros. 2008 May;7(3):179-96.
7. Isoelectric focusing phenotyping and denaturing gradient gel electrophoresis genotyping: a comparison of two methods in detection of alpha-1-antitrypsin variants. Ljujic M, Topic A, Divac A, Nikolic A, Petrovic-Stanojevic N, Surlan M, Mitic-Milikic M, **Radojkovic D.** Transl Res. 2008 May; 151(5):255-9.
8. The TNFalpha receptor TNFRSF1A and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in cystic fibrosis. Stanke F, Becker T, Cuppens H, Kumar V, Cassiman JJ, Jansen S, **Radojkovic D**, Siebert B, Yarden J, Ussery DW, Wienker TF, Tümmler B. Hum Genet. 2006 Apr; 119(3):331-43.